Literature DB >> 19352366

Development trends for therapeutic antibody fragments.

Aaron L Nelson1, Janice M Reichert.   

Abstract

Mesh：

Substances：

Year:  2009        PMID： 19352366     DOI： 10.1038/nbt0409-331

Source DB:  PubMed          Journal:  Nat Biotechnol        ISSN： 1087-0156            Impact factor:   54.908


× No keyword cloud information.
  34 in total

1.  From sorting endosomes to exocytosis: association of Rab4 and Rab11 GTPases with the Fc receptor, FcRn, during recycling.

Authors:  E Sally Ward; Cruz Martinez; Carlos Vaccaro; Jinchun Zhou; Qing Tang; Raimund J Ober
Journal:  Mol Biol Cell       Date:  2005-02-02       Impact factor: 4.138

2.  The price of sight--ranibizumab, bevacizumab, and the treatment of macular degeneration.

Authors:  Robert Steinbrook
Journal:  N Engl J Med       Date:  2006-10-05       Impact factor: 91.245

Review 3.  Monoclonal antibodies as innovative therapeutics.

Authors:  Janice M Reichert
Journal:  Curr Pharm Biotechnol       Date:  2008-12       Impact factor: 2.837

4.  Rapid tumor penetration of a single-chain Fv and comparison with other immunoglobulin forms.

Authors:  T Yokota; D E Milenic; M Whitlow; J Schlom
Journal:  Cancer Res       Date:  1992-06-15       Impact factor: 12.701

5.  Escherichia coli secretion of an active chimeric antibody fragment.

Authors:  M Better; C P Chang; R R Robinson; A H Horwitz
Journal:  Science       Date:  1988-05-20       Impact factor: 47.728

Review 6.  Physiological barriers to delivery of monoclonal antibodies and other macromolecules in tumors.

Authors:  R K Jain
Journal:  Cancer Res       Date:  1990-02-01       Impact factor: 12.701

7.  Protein engineering of antibody binding sites: recovery of specific activity in an anti-digoxin single-chain Fv analogue produced in Escherichia coli.

Authors:  J S Huston; D Levinson; M Mudgett-Hunter; M S Tai; J Novotný; M N Margolies; R J Ridge; R E Bruccoleri; E Haber; R Crea
Journal:  Proc Natl Acad Sci U S A       Date:  1988-08       Impact factor: 11.205

Review 8.  Development trends for monoclonal antibody cancer therapeutics.

Authors:  Janice M Reichert; Viia E Valge-Archer
Journal:  Nat Rev Drug Discov       Date:  2007-05       Impact factor: 84.694

9.  Differential metabolic patterns of iodinated versus radiometal chelated anticarcinoma single-chain Fv molecules.

Authors:  M E Schott; D E Milenic; T Yokota; M Whitlow; J F Wood; W A Fordyce; R C Cheng; J Schlom
Journal:  Cancer Res       Date:  1992-11-15       Impact factor: 12.701

Review 10.  Properties, production, and applications of camelid single-domain antibody fragments.

Authors:  M M Harmsen; H J De Haard
Journal:  Appl Microbiol Biotechnol       Date:  2007-08-18       Impact factor: 4.813
View more
  94 in total

Review 1.  Molecular engineering of antibodies for therapeutic and diagnostic purposes.

Authors:  Frédéric Ducancel; Bruno H Muller
Journal:  MAbs       Date:  2012-07-01       Impact factor: 5.857

2.  The future of monoclonal antibody technology.

Authors:  Alexander Zider; Donald L Drakeman
Journal:  MAbs       Date:  2010-07-01       Impact factor: 5.857

Review 3.  Strategies and challenges for the next generation of therapeutic antibodies.

Authors:  Alain Beck; Thierry Wurch; Christian Bailly; Nathalie Corvaia
Journal:  Nat Rev Immunol       Date:  2010-05       Impact factor: 53.106

Review 4.  Metrics for antibody therapeutics development.

Authors:  Janice M Reichert
Journal:  MAbs       Date:  2010-11-01       Impact factor: 5.857

5.  Chemically self-assembled antibody nanorings (CSANs): design and characterization of an anti-CD3 IgM biomimetic.

Authors:  Qing Li; Christopher R So; Adrian Fegan; Vivian Cody; Mehmet Sarikaya; Daniel A Vallera; Carston R Wagner
Journal:  J Am Chem Soc       Date:  2010-11-15       Impact factor: 15.419

Review 6.  Continuing pursuit for ideal systemic anticancer radiotherapeutics.

Authors:  Marlein Miranda Cona; Huaijun Wang; Junjie Li; Yuanbo Feng; Feng Chen; Peter de Witte; Alfons Verbruggen; Yicheng Ni
Journal:  Invest New Drugs       Date:  2011-10-18       Impact factor: 3.850

7.  A fibronectin scaffold approach to bispecific inhibitors of epidermal growth factor receptor and insulin-like growth factor-I receptor.

Authors:  Stuart L Emanuel; Linda J Engle; Ginger Chao; Rong-Rong Zhu; Carolyn Cao; Zheng Lin; Aaron P Yamniuk; Jennifer Hosbach; Jennifer Brown; Elizabeth Fitzpatrick; Jochem Gokemeijer; Paul Morin; Brent A Morse; Irvith M Carvajal; David Fabrizio; Martin C Wright; Ruchira Das Gupta; Michael Gosselin; Daniel Cataldo; Rolf P Ryseck; Michael L Doyle; Tai W Wong; Raymond T Camphausen; Sharon T Cload; H Nicholas Marsh; Marco M Gottardis; Eric S Furfine
Journal:  MAbs       Date:  2011-01-01       Impact factor: 5.857

8.  Engineered soluble monomeric IgG1 CH3 domain: generation, mechanisms of function, and implications for design of biological therapeutics.

Authors:  Tianlei Ying; Weizao Chen; Yang Feng; Yanping Wang; Rui Gong; Dimiter S Dimitrov
Journal:  J Biol Chem       Date:  2013-07-18       Impact factor: 5.157

9.  Engineering upper hinge improves stability and effector function of a human IgG1.

Authors:  Boxu Yan; Daniel Boyd; Timothy Kaschak; Joni Tsukuda; Amy Shen; Yuwen Lin; Shan Chung; Priyanka Gupta; Amrita Kamath; Anne Wong; Jean-Michel Vernes; Gloria Y Meng; Klara Totpal; Gabriele Schaefer; Guoying Jiang; Bartek Nogal; Craig Emery; Martin Vanderlaan; Paul Carter; Reed Harris; Ashraf Amanullah
Journal:  J Biol Chem       Date:  2011-12-27       Impact factor: 5.157

10.  Engineering and characterization of the chimeric antibody that targets the C-terminal telopeptide of the α2 chain of human collagen I: a next step in the quest to reduce localized fibrosis.

Authors:  Jolanta Fertala; Andrzej Steplewski; James Kostas; Pedro Beredjiklian; Gerard Williams; William Arnold; Joseph Abboud; Anshul Bhardwaj; Cheryl Hou; Andrzej Fertala
Journal:  Connect Tissue Res       Date:  2013-04-15       Impact factor: 3.417
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.